// App-Quantinova.ai

4127 : Bolus high-dose neoadjuvant sunitinib treatment overcomes potential for rebound growth during pre-surgical treatment breaks

Researchers

Presenter

  • Michalis Mastri

Principal Investigators

  • Amanda Tracz

  • Li Shen

  • Roberto Pili

  • John M.L. Ebos

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 31

  • Proliferation marker protein Ki-67

  • Kinase Insert Domain Receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Sunitinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved